This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Do Options Traders Know Something About Celsion (CLSN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.
CLSNNegative Net Change
biotechs medical
Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).
REGNNegative Net Change SNYNegative Net Change INCYNegative Net Change LLYNegative Net Change KMPHPositive Net Change ASLNNegative Net Change VIRNegative Net Change
biotechs
Blueprint Medicines (BPMC) Gets EMA Validation for Ayvakyt in SM
by Zacks Equity Research
The EMA validates Blueprint Medicines' (BPMC) Type II variation marketing authorization application for Ayvakyt to treat advanced systemic mastocytosis.
RGENNegative Net Change CLBSPositive Net Change NBRVPositive Net Change
biotechs
5 ETF Investing Areas for March to Boost Returns
by Sweta Jaiswal, FRM
Here we discuss a few ETFs that can enrich investors' portfolio in March amid a strong wave of optimism surrounding the coronavirus vaccine and introduction of another round of fiscal stimulus.
JNJNegative Net Change XLENegative Net Change IBBNegative Net Change XBINegative Net Change FMATNegative Net Change IBUYPositive Net Change BOTZNegative Net Change SKYYPositive Net Change CLIXPositive Net Change ROBTNegative Net Change CLOUPositive Net Change
basic-materials biotechs cloud-computing cybersecurity e-commerce etfs finance
Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails
by Zacks Equity Research
Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.
MRNANegative Net Change ARNAPositive Net Change LXRXNegative Net Change RGENNegative Net Change
biotechs
Why ADC Therapeutics (ADCT) Might Surprise This Earnings Season
by Zacks Equity Research
ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ADCTNegative Net Change
biotechs earnings
ChemoCentryx (CCXI) Q4 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the fourth quarter and misses on sales.
ZTSPositive Net Change CCXIPositive Net Change SAVAPositive Net Change
biotechs earnings
Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Beat on Galafold
by Zacks Equity Research
Amicus (FOLD) reports a wider-than-expected Q4 loss but sales beat estimates.
SNYNegative Net Change RHHBYNegative Net Change FOLDPositive Net Change TAKNegative Net Change
biotechs earnings
Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.
LXRXNegative Net Change RGENNegative Net Change NBRVPositive Net Change KODPositive Net Change
biotechs earnings
Stocks Off to a Solid Start in March: 6 Bargain ETF Picks
by Sweta Killa
Given the jump in investors' sentiment, ETFs that still trade at bargain price seem excellent pick.
JNJNegative Net Change SPYNegative Net Change IEONegative Net Change XBINegative Net Change SDIVNegative Net Change IAKNegative Net Change FDMPositive Net Change DEEPNegative Net Change
biotechs energy etfs finance
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.
MRNANegative Net Change SRPTPositive Net Change LXRXNegative Net Change RGENNegative Net Change
biotechs earnings
Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
LLYNegative Net Change AMGNPositive Net Change ABBVNegative Net Change BHVNNegative Net Change
biotechs earnings
Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA
by Zacks Equity Research
Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome. Stock rises.
LXRXNegative Net Change RGENNegative Net Change ABBVNegative Net Change RETAPositive Net Change
biotechs earnings
Axsome's (AXSM) Q4 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.
LXRXNegative Net Change RGENNegative Net Change AXSMPositive Net Change NBRVPositive Net Change
biotechs earnings
Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates
by Zacks Equity Research
Novavax's (NVAX) fourth-quarter 2020 loss is wider than estimates. Sales beat the same.
SNYNegative Net Change ACORPositive Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs
Markets Up Big Monday; Zoom (ZM) Beats, Novavax (NVAX) Misses Q4
by Mark Vickery
The Dow rose 1.95% on the day, +603 points; the S&P 500 gained 2.38%; the Nasdaq rose 3%, nearly 400 points; and the small-cap Russell 2000 took the cake, +3.37%.
NVAXNegative Net Change ZMPositive Net Change
biotechs tech-stocks
Denali's (DNLI) Q4 Earnings & Revenues Beat on Biogen Deal
by Zacks Equity Research
Denali (DNLI) posts earnings in the fourth quarter of 2020 due to collaboration revenues from Biogen.
BIIBNegative Net Change SNYNegative Net Change DNLINegative Net Change TAKNegative Net Change
biotechs earnings
Acceleron (XLRN) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Acceleron (XLRN) reports a wider loss in the fourth quarter of 2020 on higher costs and lower revenues.
INCYNegative Net Change NVSNegative Net Change BMYNegative Net Change XLRNPositive Net Change
biotechs
Top Stock Picks for Week of March 1, 2021
by Panel Of Zacks Experts
A Leader in Covid-19 Vaccine and a Company Showing Positivity.
MRNANegative Net Change SEPositive Net Change
biotechs tech-stocks
Aerie (AERI) Rises Despite Q4 Earnings Miss, Revenues Top Mark
by Zacks Equity Research
Aerie (AERI) up more than 16% despite reporting a wider-than-expected loss in the fourth quarter of 2020. Revenues beat estimates.
PFENegative Net Change CANFPositive Net Change AERIPositive Net Change OPHLFNo Net Change
biotechs earnings
FDA Emergency Nod for J&J COVID-19 Vaccine Heats Up Competition
by Kinjel Shah
J&J's (JNJ) single shot COVID-19 vaccine gets FDA emergency use authorization. U.S. CDC Advisory Committee also recommends J&J's vaccine.
JNJNegative Net Change AZNNegative Net Change PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change
biotechs pharmaceuticals
Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Intercept (ICPT) posts a wider loss and misses on sales in the fourth quarter of 2020.
NVONegative Net Change GILDNegative Net Change VKTXNegative Net Change ICPTPositive Net Change
biotechs earnings
Radius' (RDUS) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Radius (RDUS) reports a wider loss but beats sales estimates in the fourth quarter.
ENDPPositive Net Change LLYNegative Net Change AMGNPositive Net Change
biotechs earnings pharmaceuticals
Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus
by Zacks Equity Research
Apellis' (APLS) bottom line grows year over year in the fourth quarter of 2020 while revenues beat estimates. Main focus of the company is on lead pipeline candidate, pegcetacoplan.
ALXNPositive Net Change LXRXNegative Net Change NBRVPositive Net Change APLSPositive Net Change
biotechs earnings
Iovance (IOVA) Q4 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) fourth-quarter earnings miss estimates. The company is progressing well with development of its lead pipeline candidate.
MRKNegative Net Change BMYNegative Net Change LXRXNegative Net Change IOVAPositive Net Change
biotechs earnings